arrow
A

Arnold Baars

Leiden University
H指数:19
被引数:2,912

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort study

氟嘧啶类为基础的化疗中老年患者耐受性差的预测因素:一项前瞻性队列研究

2026-04-020
OAAI
Death Anxiety During the Last Year of Life in Patients With Advanced Cancer: Longitudinal Results From the eQuiPe Study

晚期癌症患者生命最后一年中的死亡焦虑:eQuiPe研究的纵向结果

2026-03-160
PRE
Sexual health at the end of life in patients with advanced cancer and their partners. Results of a Dutch prospective longitudinal study (eQuiPe)

晚期癌症患者及其伴侣生命终末期的性健康。荷兰前瞻性纵向研究(eQuiPe)结果

2025-11-140
OA
Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity

微生物维生素生物合成将肠道微生物群动态与化疗毒性联系起来

MBIO
IF4.7
2025-06-110
OA
Socioeconomic disparities in health-related quality of life and healthcare use in the last year of life of patients with advanced cancer: longitudinal results from the eQuiPe study

晚期癌症患者临终前一年健康相关生活质量与医疗资源利用的社会经济差异:eQuiPe研究的纵向结果

2025-03-110
OA
Dose-individualisation of fluoropyrimidines in DPYD wild-type patients: Final results from the Alpe2U study

氟嘧啶类药物的剂量个体化在DPYD野生型患者中的研究:Alpe2U研究的最终结果

2024-09-011
PRE
Trajectories of health-related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study

生命末期晚期癌症患者与健康相关的生活质量和症状负担的轨迹: eQuiPe研究的纵向结果

CANCER
IF5.1
2023-10-1313
PRE
Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial
2020-11-1147
OAAI
Fasting mimicking diet as an adjunct toneoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
2020-06-23194
OAAI
DIetary REstriction as an adjunct to neoadjuvant ChemoTherapy for HER2-negative breast cancer: Final results from the DIRECT trial (BOOG 2013-04)
2019-02-151
PRE
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

基于氟嘧啶的抗癌治疗中前期DPYD基因型指导剂量个体化的成本分析

2019-01-0170
OAAI